Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca ...

Herrington Management Publishes Independent Analysis on Maximizing Hilton Honors Points Value

Herrington Management has published an editorial brief examining the strategic use of Hilton Honors points for travel redemptions. The independent analysis provides data-driven insights to help ...